Background: Multitarget-directed ligands (MTDLs), particularly those combining cholinesterase inhibition with additional mechanisms, are promising candidates for Alzheimer’s disease (AD) therapy. Here, BCHE is linked to early-onset autosomal dominant Alzheimer disease.